Study to Evaluate the Safety and PK of Elpida® in Healthy Subjects and Patients With Hepatic Impairment and to Assess the Impact of Food Intake and Drug-Drug Interactions With Other Antiviral Drugs

NCT03706898 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV-1-infection
Hepatic Impairment

Interventions

DRUG: Elpida®
DRUG: Dolutegravir
DRUG: Sofosbuvir
DRUG: Daclatasvir

Sponsor

Viriom